The cost-effectiveness analysis of initiating HIV/AIDS treatment with efavirenz-based regimens compared with nevirapine-based regimens in Thailand.
Artículo
en Inglés
| IMSEAR
| ID: sea-38822
ABSTRACT
OBJECTIVES:
The aim of this study is to evaluate the cost-utility of the treatment, starting with EFZ-based therapy, compared with NVP-based therapy in Thai HIV/AIDS patients. MATERIAL ANDMETHOD:
The study adopted a health care provider perspective. A probabilistic Markov model was applied to Thai HIV/AIDS patients aged 15 to 65 years. Input parameters were extracted from a cohort study of four regional hospitals. The study explored the effects of uncertainty around input parameters.RESULTS:
For those patients with a different baseline CD4, initial therapy using EFZ-based regimens was the preferable choice for all subgroups. Given a maximum acceptable willingness to pay (WTP) threshold of 300,000 Baht/DALY averted starting with EFZ-based regimens was cost-effective for patients with a baseline CD4 count less than 250 cells/mm3 and in all patient age groups, except those who were 20 years old.CONCLUSIONS:
The results suggest that starting with EFZ-based regimens was the preferable choice and it should be used as the first line regimen for Thai HIV/AIDS patients.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Tailandia
/
Anciano
/
Femenino
/
Humanos
/
Masculino
/
Infecciones por VIH
/
Probabilidad
/
Estudios de Cohortes
/
Cadenas de Markov
/
Adolescente
Tipo de estudio:
Estudio de etiología
/
Evaluación Económica en Salud
/
Estudio de incidencia
/
Estudio observacional
/
Estudio pronóstico
/
Factores de riesgo
País/Región como asunto:
Asia
Idioma:
Inglés
Año:
2008
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS